LB Pharmaceuticals Inc LBRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -85.69M | -38.95M | -- | -- | -- |
| Total Depreciation and Amortization | 345.00K | 324.00K | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.03M | 5.89M | -- | -- | -- |
| Change in Net Operating Assets | -8.09M | -17.63M | -- | -- | -- |
| Cash from Operations | -82.40M | -50.37M | -- | -- | -- |
| Capital Expenditure | -435.00K | -63.00K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -44.38M | -44.84M | -- | -- | -- |
| Cash from Investing | -44.82M | -44.90M | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 428.07M | 428.03M | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -31.70M | -31.63M | -- | -- | -- |
| Cash from Financing | 396.37M | 396.39M | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 269.16M | 301.12M | -- | -- | -- |